<DOC>
	<DOCNO>NCT01857752</DOCNO>
	<brief_summary>Primary Objectives : 1 . To investigate response rate ( complete response plus partial response ) temozolomide 8 week ( 2 cycle ) , patient retinoblastoma metastatic central nervous system ( mass ) two stratum : - A . Initial diagnosis ( mass ) - B . At relapse ( mass ) 2 . To determine hematologic toxicity : absolute neutrophil count ( ANC ) , platelet hemoglobin count . Secondary Objectives : 1 . To determine response metastatic site ( non target ) ( orbit , bone marrow , bone , lung , liver others ) 2 . To determine remission rate time relapse temozolomide . 3 . To document response leptomeningeal metastasis ( cerebrospinal fluid ) temozolomide</brief_summary>
	<brief_title>Phase II Study Temozolomide Retinoblastoma Metastatic Central Nervous System Patients From Guatemala</brief_title>
	<detailed_description />
	<mesh_term>Retinoblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>1 . This study must evaluate confirm local ethic committee institutional review board participate institution , accordance declaration Helsinki . Informed consent must administer parent guardian must sign document , authorize Ethics Committee human subject ( therapy start document sign ) . 2 . Patients le 21 year age diagnosis retinoblastoma metastasis CNS ( central nervous system ) must confirm ophthalmologist and/or pathologist ; conjunction pediatric oncologist . 3 . Metastasis CNS define mass chiasm site CNS , confirm MRI and/or CT : 1 . At diagnosis 2 . At relapse conventional therapy . It acceptable sit metastatic disease : lymphatic , bone , bone marrow others . 4 . All sit metastasis must measure 3 plane , millimeter describe POND ( Pediatric Oncology Network Database* ) 5 . Quality life must 3 Lansky 50 % Karnofksy 6 . Hemogram : Hemoglobin 7 , ANC 750 , platelet 75K . 7 . Chemistry : direct bilirubin less 3.0 , indirect bilirubin less 4.0 , AST le 5x normal ALT 5x normal , creatinine less 1.5 . 8 . Treatment must start 15 day diagnosis metastatic retinoblastoma . 9 . Every patient relapse progression CNS must document CT scan MRI brain . Other site relapse may evaluate , include bone marrow . 10 . Patients newly diagnose receive chemotherapeutic therapy ( exception dexamethasone ) 1 week starting , radiotherapy , 4 week start . 11 . All patient include study must present principal investigator use Horizon Live Webconferencing Cure4Kids website . Eligibility target CNS site determine , well nontarget site . 1 . Patients metastatic CNS CSF involvement NOT ELIGIBLE . 2 . Relapse patient NOT receive chemotherapy 4 week , patient receive nitroureas ( melphalan , CCNU mustard ) . No patient receive radiation therapy previous 42 day . These patient NOT eligible . 3 . Diagnosis AIDS HIV positive . 4 . Patients disease NOT CNS NOT eligible</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Retinoblastoma</keyword>
</DOC>